Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
07/15/2022* -- Results Q3 2022 -- -0.28 --
01/14/2022 -- Results Q1 2022 -- -- --
11/29/2021 -- Results Q4 2021 -- -- --
07/15/2021 -- Results Q3 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 07/15/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 01/14/2022
Beat/Miss Upgrade
Return Since -33.41%
Last FQE 02/28/2022
Next FQE 05/28/2022

Profile

Edit
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio.
URL https://www.lexariabioscience.com
Investor Relations URL http://www.lexariaenergy.com/investors/
HQ State/Province British Columbia
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Jul. 15, 2022 (est.)
Last Earnings Release Jan. 14, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
110.0%
93.75%
445.2%
-44.97%
-58.87%
-34.82%
-46.12%
-23.82%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-19.77%
-32.14%
-14.98%
115.7%
50.55%
197.1%
-31.74%
65.37%
-49.54%
-44.04%
-68.72%
-60.09%
-83.95%
-24.91%
3.66%
32.47%
-70.34%
47.27%
-31.65%
-37.82%
-81.28%
-95.69%
-49.88%
-74.05%
-58.62%
-59.29%
-4.23%
-63.31%
123.4%
107.8%
17.32%
103.1%
1.50%
As of June 23, 2022.

Profile

Edit
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio.
URL https://www.lexariabioscience.com
Investor Relations URL http://www.lexariaenergy.com/investors/
HQ State/Province British Columbia
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Jul. 15, 2022 (est.)
Last Earnings Release Jan. 14, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter LEXX Tweets